UroGen Pharma’s Post

According to results from the phase 2 NICHE-2 trial, neoadjuvant nivolumab plus ipilimumab showed promising safety and response results among patients with locally advanced mismatch repair-deficient colon cancer. Learn more: https://lnkd.in/ec2bZMTN

💫 DESTINY-Breast06 Phase III trial 💫 🌟 Enhertu demonstrated significant & clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy 🔗 https://buff.ly/3UokfbM

Extracellular vesicles from pancreatic cancer and its tumour microenvironment promote increased Schwann cell migration https://lnkd.in/eya5wu3k

A tailored approach with nivolumab using nivolumab plus ipilimumab as immunotherapeutic boost represents an effective option in second-/third-line metastatic urothelial cancer, especially with high-dose ipilimumab regarding response and survival outcome. https://ja.ma/4acnut0

The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in neoadjuvant treatment of HER2-positive, ER/PR-negative early or locally advanced breast cancer, offering a cost-effective alternative with comparable clinical outcomes. https://bit.ly/3VAdTYy

Exploring optimal administration timing of pegylated recombinant human granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in early breast cancer treated with pharmorubicin and endoxan: a prospective randomized controlled clinical trial https://lnkd.in/ekMQwpP6 🧪 @BioMedCentral #CancerResearch

Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer   Updated overall survival (OS) results - a key secondary endpoint - reinforce the significant benefit of the ItovebiTM (inavolisib)-based regimen for patients with advanced PIK3CA-mutated, HR-positive, HER2-negative breast cancer in the first-line setting Primary analysis showed the Itovebi-based regimen reached statistical significance, more than doubling progression-free survival in this patient population1 Full OS results from the phase III INAVO120 study will be presented at an upcoming medical meeting

Health care systems are heterogeneous, and in systems with limited resources, it is crucial to optimize therapy by offering the best possible treatment within the reality of each system. Cyclophosphamide may play a role in the treatment of men with metastatic castration-resistant prostate cancer in specific scenarios— a real-world uro-oncology practice study. Published yesterday in JCO ASCO https://lnkd.in/ea5f3u3Q

Imfinzi (durvalumab) + Imjudo (tremelimumab) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA phase III trial - AstraZeneca https://lnkd.in/estJrQtY

Exploring optimal administration timing of pegylated recombinant human granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in early breast cancer treated with pharmorubicin and endoxan: a prospective randomized controlled clinical trial https://lnkd.in/ehK3ZW4w 🧪 @BioMedCentral #CancerResearch